Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3211191 | 0.88 | ALDH1A1 (0.61) | ALDH1A1TSHRGAANFKB1TDP1 | |
| SCHEMBL5940445 | 0.88 | ALDH1A1 (0.64) | ALDH1A1TDP1 | |
| SCHEMBL5833247 | 0.85 | TAAR1 (0.62) | ALDH1A1TSHRGAANFKB1TDP1 | |
| SCHEMBL7768865 | 0.82 | FOS (0.62) | ALDH1A1TSHRGAANFKB1TDP1 | |
| SCHEMBL11069853 | 0.81 | GAA (0.67) | ALDH1A1TSHRGAANFKB1TDP1 | |
| SCHEMBL297477 | 0.81 | ALDH1A1 (0.64) | ALDH1A1TSHRGAANFKB1TDP1 | |
| SCHEMBL28057106 | 0.81 | TRPV1 (0.71) | ALDH1A1TSHRGAAALOX5TRPV1 | |
| SCHEMBL11856806 | 0.81 | TAAR1 (0.57) | ALDH1A1TSHRGAANFKB1TDP1 | |
| Undecanoate SCHEMBL28314051 | 0.80 | CYP1A2 (0.67) | ALDH1A1TRPV1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2663140 | 0.80 | ALDH1A1 (0.51) | ALDH1A1TSHRGAANFKB1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118866141-A | Metabolic-study-based method for determining origin tracing of wild chubs in Yangtze river and application | 中国水产科学研究院长江水产研究所 | 2024-10-29 | — | — | CN | claimed |
| EP-2353016-A1 | NON-HUMAN ANIMALS HAVING PSYCHIATRIC DISORDERS, METHOD FOR OBTAINING SAME, AND USE THEREOF FOR DRUG SCREENING | Université Henri Poincaré Nancy 1 (FR) | 2011-08-10 | — | — | EP | claimed |
| WO-2010034960-A1 | NON-HUMAN ANIMALS HAVING PSYCHIATRIC DISORDERS, METHOD FOR OBTAINING SAME, AND USE THEREOF FOR DRUG SCREENING | UNIVERSITE HENRI POINCARE NANCY 1 (FR) | 2010-04-01 | — | — | WO | claimed |
| CN-122055354-A | Lipid compounds and related compositions and uses | 波西达治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-118866141-A | Metabolic-study-based method for determining origin tracing of wild chubs in Yangtze river and application | 中国水产科学研究院长江水产研究所 | 2024-10-29 | — | — | CN | disclosed |
| CN-118225951-A | Marker group for major depressive disorder and screening method and application thereof | 上海大学 | 2024-06-21 | — | — | CN | disclosed |
| EP-2008110-B1 | METHOD FOR DIAGNOSING IN VITRO OR EX VIVO PSYCHIATRIC DISORDERS AND/OR INTESTINAL DYSBIOSES | UNIVERSITÉ HENRI POINCARÉ NANCY 1 (FR) | 2017-03-22 | — | — | EP | disclosed |
| EP-2353016-A1 | NON-HUMAN ANIMALS HAVING PSYCHIATRIC DISORDERS, METHOD FOR OBTAINING SAME, AND USE THEREOF FOR DRUG SCREENING | Université Henri Poincaré Nancy 1 (FR) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010034960-A1 | NON-HUMAN ANIMALS HAVING PSYCHIATRIC DISORDERS, METHOD FOR OBTAINING SAME, AND USE THEREOF FOR DRUG SCREENING | UNIVERSITE HENRI POINCARE NANCY 1 (FR) | 2010-04-01 | — | — | WO | disclosed |
| US-20100028901-A1 | METHOD FOR DIAGNOSING IN VITRO OR EX VIVO PSYCHIATRIC DISORDERS AND/OR INTESTINAL DYSBIOSES | AURE (FR) | 2010-02-04 | — | — | US | disclosed |
| EP-2008110-A2 | METHOD FOR DIAGNOSING IN VITRO OR EX VIVO PSYCHIATRIC DISORDERS AND/OR INTESTINAL DYSBIOSES | AURE (FR) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007119004-A2 | METHOD FOR DIAGNOSING IN VITRO OR EX VIVO PSYCHIATRIC DISORDERS AND/OR INTESTINAL DYSBIOSES | AURE (FR) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028901-A1 | METHOD FOR DIAGNOSING IN VITRO OR EX VIVO PSYCHIATRIC DISORDERS AND/OR INTESTINAL DYSBIOSES | DBH, CRH, SI | ALDH1A1 1095/4885TSHR 3056/4885GAA 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.